MNI AntaGolin 60 Tablets

MNI AntaGolin 60 Tablets is made with a special blend of phytochemical compounds derived from barberry root and banana leaf extracts, and inositol to help regulate blood sugar and fats in the body.

Detailed Description:
Proprietary name and dosage form. Composition. Active: each tablet contains: Insul-X2™ Contains barberry root extract (berberis vulgaris) - 35mg. -Other ingredients include chromium - 400mg. Banaba leaf extract (lagerstroemia speciosa) - 400mg. Inositol - 40mg. Excipients: Microcrystalline cellulose, dicalcium phosphate, maize starch, silicon dioxide, croscarmellose sodium, magnesium stearate, shellac. Pharmacological classification: A. 21.2 oral hypoglycaemic agents. Pharmacological action: AntaGolin™ contains a blend of phytochemical (plant-derived) compounds that aid with the metabolic regulation of blood sugar and blood fats. These are barberry root extract, banaba leaf extract and inositol. Barberry root extract: Insul-X2™ is a proprietary formulation prepared from barberry root extract. Its main constituent is the botanical alkaloid berberine [C20 H18 NO4], naturally found in the roots, stems and bark of plants such as Chinese goldthread (coptis chinensis), barberry (berberis vulgaris) and goldenseal (hydrastis canadensis). Berberine has historically been used in both ayurvedic and Chinese traditional medicine for over a thousand years. Customarily, its medicinal applications include the treatment of obesity and diabetes. Berberine has been tested in various animal, experimental and human studies and over two thousand publications on berberine appear in scientific literature. These include studies conducted on human subjects, where the effects of berberine were examined in relation to several medical conditions commonly associated with the metabolic syndrome. This disorder is characterised by the accumulation of excess body fat and the development of insulin resistance, hyperlipidaemia and type 2 diabetes. Clinical trials have investigated the effects of berberine on blood sugar levels in type 2 diabetic patients. In all trials, significant decreases were measured in various metabolic parameters which include fasting blood glucose, HbA1c and triglyceride levels. Yin J (2008), Zhang Y (2009), Zhang H (2009). Other researchers have investigated the molecular basis of berberine's role in blood glucose control in vivo. Research using four different biological cell lines has demonstrated that berberine stimulates glucose uptake in a manner that is distinctly different to that of insulin. Analysis has also shown that although berberine mimics the role of insulin regarding the cellular transport of glucose across cell membranes, this function appears to be independent of insulin, thereby suggesting that less insulin is required to achieve the same end result. In this role berberine can therefore be considered to be insulin sparing. Chen Z (2006), Zhou L (2006), Kim SH (2007), Yin J (2008). In various experiments using several biological cell models primed for insulin resistance, berberine demonstrated the ability to up-regulate insulin receptor (insR) expression, thereby positively identifying insR as a primary biological target of berberine. Zang H (2009) Wang YX (2009) the InsR-up-regulating and glucoselowering activities of berberine has also been investigated in humans. A study involving a variety of human cell lines including CEM, HCT-116, SW1990, HT1080, 293T, and hepatitis b virus-transfected human liver cells showed that berberine increased insR messenger RNA and protein expression in cultured cells Kon WJ (2008). In all studies, it was demonstrated that berberine caused an improvement in glucose tolerance and enhanced insulin action, thereby reducing insulin resistance. Ko BS (2005), Lee YS (2006), Yi P (2008), Chen Y (2009). A number of preliminary in vivo studies conducted on test animals have demonstrated that berberine has the ability to alleviate insulin resistance. In some studies, this was also accompanied by a reduction in body weight, in particular body fat, without altering the food intake of test animals. Several investigators have researched this phenomenon in vitro; exploring the molecular role that berberine plays regarding the differentiation of pre-adipocytes (connective tissue fibroblasts) into adipocytes (mature fat cells), a process that requires several transcription factors. Various experimental studies using animal cell lines have demonstrated that berberine suppresses the differentiation of 3T3-L1 pre-adipocytes into mature adipocytes through a molecular pathway that involves PPAR-Y, a transcription factor that mediates the transcription of several genes related to fatty acid synthesis, transport and storage. Choi BH (2006) Huang C (2006). In a separate study evaluating the transcriptional impact of berberine in human cells, it was demonstrated that berberine significantly inhibited the differentiation of human white pre-adipocyte (HWP) into adipocytes, thereby displaying the potential to moderate adipose tissue mass. Hu Y (2009). Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disorder commonly associated with insulin resistance (IR) and the accumulation of excess body fat. A randomised, placebo controlled study involving 89 subjects with PCOS and IR was conducted. In all cases the presence of insulin resistance was confirmed via the homeostasis model assessment for IR (HOMA-IR), fasting glucose insulin ratio (FGIR) and fasting insulin (FIN). Various clinical, metabolic and hormonal parameters were assessed in the subjects before and after treatment. As compared to placebo, post treatment results for berberine demonstrated a significant improvement in insulin sensitivity and a substantial reduction in fasting insulin (FIN) levels, as well as a decrease in waist circumference and waist to-hip ratio. Wei W (2012). Banaba leaf extract: Banaba (lagerstroemia speciosa) is a medicinal plant that grows in India, Southeast Asia and the Philippines. Extracts of the leaves are used in Eastern traditional medicine to treat type 2 diabetes and kidney related diseases. Compared to berberine, banaba is a relatively new entry into the herbal pharmacopeia with recorded use dating back over a hundred years and the first published research study appearing in 1940. Biochemical investigations conducted on banaba leaf extract using various biological cell models have explored the pharmacologically active elements. Two dominant groups of phyto-chemical compounds have been identified. These are corosolic acid (C30 H48 O4], a pentacyclic triterpene, and lagerstroemin, flosin B and reginin, all ellagitannins that belong to the polyphenol family. Various outcome based studies have demonstrated that banaba leaf extract displays beneficial effects relating to the regulation of blood sugar levels in individuals with type 2 diabetes. Tsuchibe (2006), Fukushima (2006) Xu (2008). In all treatment groups a statistically significant decrease in both fasting and postprandial blood glucose were observed. Studies also suggest that banaba leaf extract may offer various health benefits to overweight or obese individuals that are not yet diabetic. Experimental testing using various different cell models demonstrated that banaba leaf extract enhances the cellular uptake of glucose, improves insulin sensitivity and inhibits the intestinal digestion of sucrose (table sugar). Kim HJ (2012) G Sivakumar (2009) Shi L (2007) Miura T (2012). Inositol: Inositol is a carbohydrate that is naturally present in a variety of foods, the highest concentrations being fruits, especially cantaloupe and oranges, and as a component of phosphates or phospholipids in beans, grains and nuts. Inositol occurs in 9 different stereoisomeric forms, with myo-inositol being the most dominant and widely distributed in nature. Myo-inositol is readily converted though epimerisation into other isomeric forms. L-chiro-inositol and d-chiro-inositol, for example, are respectively produced from myo-inositol in situ via the epimerisation of the hydroxyl #1 or # 3 group of myo-inositol. Inositol in its various isomers plays an important role as the structural basis for a number of signalling and secondary messenger molecules involved in several biological processes. This includes insulin signal transduction. Early studies have demonstrated a linear relationship between decreased urinary inositol excretion and the degree of insulin resistance present, suggesting that an inositol deficiency may form part of the complex mechanism that leads to insulin resistance. Administration of inositol to diabetic rats, rhesus monkeys and now humans, was found to accelerate glucose disposal and sensitise insulin action, Larner J (2002). Two studies involving young women suffering from the polycystic ovary syndrome (PCOS) have examined the effects of inositol supplementation in the D-chiro isomer form in relation to many of the clinical hallmarks associated with PCOS. This included insulin resistance, hyperandrogenism and oligo-amenorrhea. Nestler HE (1999), Luorno M (2002). In both studies, it was found that inositol supplementation increased the action of insulin in patients with PCOS and as a consequence, improved ovulatory function whilst decreasing serum androgen concentrations, blood pressure and plasma triglyceride levels. Other studies have examined the effects of myo-inositol in relation to the metabolic syndrome in older women. In one randomised Placebo controlled study, 80 postmenopausal women affected by the metabolic syndrome were enrolled in a 6-month programme to test the effects of inositol supplementation. As compared to the placebo group (on diet and placebo supplement), the myo-inositol supplementation group (on the same diet) demonstrated an improvement in levels of insulin resistance, as measured by the HOMA index. Blood pressure, serum cholesterol and triglyceride levels were also reduced in a highly significant manner Glordano D (2011). A randomized, placebo-controlled trial involving 155 postmenopausal women fulfilling the diagnostic criteria of metabolic syndrome was conducted. All women were asked to follow the same low-calorie diet. One group were randomly assigned to a daily supplement of inositol and alpha lipoic acid, the rest to a placebo supplement. Results from this trail demonstrated a significant reduction in levels of insulin resistance, as measured by a HOMA-IR and serum insulin levels, as well as a reduction in triglycerides after six-months. A reduction in waist circumference and waist-hip-ratio was also demonstrated in the inositol supplement group. Capasso I (2013). Indications: To help stabilise blood sugar levels and help regulate certain biochemical pathways involved in the development of insulin resistance. Contraindications. Known or suspected pregnancy (see pregnancy and lactation). Breastfeeding (see pregnancy and lactation). Hypersensitivity or known allergy to any of the ingredients. Identification: Rose coloured oval tablet with no distinctive markings. Presentation: The tablets are packed into individual blister sheets made from transparent polyvinyl chloride (PVC) film and sealed with aluminium foil the name AntaGolin™ appears on the aluminium foil. Each blister contains 10 rose coloured tablets. Carton contains 6 blister sheets. Sucrose, lactose, gluten and tartrazine free. www.mnilifestyle.co.za. 60 tablets. AntaGolin™ contains a blend of ingredients recognised for their ability to help stabilise blood sugar levels and help regulate certain biochemical pathways involved in the development of insulin resistance. Consult your healthcare practitioner for a medical opinion. 

Pack size:
60 tablets

Quantity in pack:
60

Marketing description:
MNI. Medical nutritional institute. AntaGolin™. Ethical and Responsible™.

Brand:
MNI

Package type:
Box